Rubric Capital Management LP Lowers Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Rubric Capital Management LP trimmed its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,333,893 shares of the company’s stock after selling 287,141 shares during the period. Rubric Capital Management LP owned 3.07% of Werewolf Therapeutics worth $3,255,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Rhumbline Advisers bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $79,000. Lighthouse Investment Partners LLC purchased a new position in shares of Werewolf Therapeutics in the fourth quarter worth about $87,000. American Century Companies Inc. raised its stake in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Werewolf Therapeutics in the second quarter worth about $165,000. Finally, Denali Advisors LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth about $172,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL opened at $2.19 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. The business’s 50 day moving average price is $2.30 and its 200-day moving average price is $3.98. The firm has a market capitalization of $95.17 million, a PE ratio of -2.01 and a beta of 0.46. Werewolf Therapeutics, Inc. has a 1 year low of $1.57 and a 1 year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, June 26th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $9.00 price objective on shares of Werewolf Therapeutics in a report on Monday, June 3rd.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.